OTEZLA (apremilast), PDE4 inhibitor immunosuppressant

DERMATOLOGY - New medicinal product

Opinions on drugs - Posted on Apr 15 2016

Inclusion

OTEZLA (oral) has a Marketing Authorisation in the treatment of moderate to severe chronic plaque psoriasis in adult patients in case of failure, contraindication or intolerance to other systemic treatments including ciclosporin, methotrexate or PUVA therapy.
Its modest efficacy has been demonstrated compared with placebo in patients refractory to topical treatments. No clinical benefit has been demonstrated compared with other conventional or biological systemic treatments.
It is a second-line systemic treatment, after failure of other non-biological systemic treatments. It can be useful for delaying the start of treatment with biotherapy.

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account